Bisphosphonates for patients diagnosed with multiple myeloma
A partir d'une revue systématique de la littérature publiée entre 1982 et 2015 (7 293 patients), cette étude évalue l'association entre une utilisation de bisphosphonates, le risque de fractures et d'événements indésirables liés au squelette, ainsi que la mortalité chez les patients atteints d'un myélome multiple
Clinical Question : Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures, nonvertebral fractures, and skeletal-related events compared with placebo or no treatment? Bottom Line : Among patients with myeloma, bisphosphonates were associated with lower rates of pathological fractures and skeletal-related events compared with placebo or no treatment. Direct meta-analysis showed no association between bisphosphonates and mortality. In network meta-analysis, zoledronate was associated with lower risk of mortality compared with placebo or no treatment. This JAMA Clinical Evidence Synopsis summarizes a Cochrane review of the associations of specific bisphosphonates with mortality, vertebral and nonvertebral fractures, and overall skeletal-related events in the management of patients with myeloma.
JAMA 2018